Naptumomab estafenatox: a new immunoconjugate

  • Expert Opin Biol Ther. 2010 Feb;10(2):273-9. doi: 10.1517/14712590903575620.
Matthew K Robinson  1 ,  R Katherine Alpaugh ,  Hossein Borghaei
Affiliations
  • 1. Fox Chase Cancer Center, Department of Medical Oncology, 333 Cottman Ave, Philadelphia, PA 19111, USA.
PMID: 20053143 DOI: 10.1517/14712590903575620
Abstract

Importance of the field: New agents that specifically engage the immune system are being tested in a variety of malignancies. This review provides an overview of naptumomab, an immunotoxin, with encouraging clinical activity in Phase I trials.

Areas covered in this review: This review examines the preclinical and the published clinical data with regards to naptumomab.

What the reader will gain: This review provides the reader with an understanding of the mechanism of action, immunology, pharmacokinetics and clinical activity of this agent.

Take home message: Naptumomab has a unique mechanism of action and appears to be an active agent in the treatment of refractory solid tumors such as renal cell carcinoma.

Products